← ANALYST RATINGS · TIPRANKS
EyePoint Pharmaceuticals (EYPT): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy4 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $15.50, the highest $39.00, the lowest $4.00. The average is +418.4% from the last price of $2.99.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +0.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +0.3% | Reiterated | 14.10.26on TipRanks Oct 13 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +0.3% | Reiterated | 14.10.26on TipRanks Oct 13 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | +0.3% | Reiterated | 14.10.26on TipRanks Oct 13 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | +0.3% | Reiterated | 14.10.26on TipRanks Oct 13 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +0.3% | Reiterated | 14.10.26on TipRanks Oct 13 23:05 | — | |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $20.00 | Buy | +568.9% | Reiterated | 07.10.26on TipRanks 11:10 | +5.0%next day +4.6% · 5 days −8.4% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $17.00 | Buy | +468.6% | Reiterated | 09.09.26on TipRanks Sep 10 06:10 | −4.4%next day −1.5% · 5 days −19.4% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $20.00 → $4.00−80.0% | Hold | +33.8% | Downgrade | 02.09.26on TipRanks 00:30 | +4.1%next day −5.7% · 5 days −10.3% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $65.00 → $5.00−92.3% | Hold | +67.2% | Downgrade | 18.08.26on TipRanks 08:10 | +13.0%next day +15.0% · 5 days −8.3% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | — | Hold | — | Downgrade | 18.08.26on TipRanks 06:15 | +13.0%next day +15.0% · 5 days −8.3% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $30.00 → $8.00−73.3% | Buy | +167.6% | Reiterated | 17.08.26on TipRanks Aug 18 04:00 | −66.5%next day +13.0% · 5 days +1.2% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $37.00 → $5.00−86.5% | Hold | +67.2% | Downgrade | 17.08.26on TipRanks 21:00 | +13.0%next day +15.0% · 5 days −8.3% | ↗ |
| Yale Jen★★★★★★★★★★#11895 · hits 27% · avg −9.0% | Laidlaw | $50.00 → $48.00−4.0% | Buy | +1,505.4% | Reiterated | 17.08.26on TipRanks 15:45 | −66.5%next day +13.0% · 5 days +1.2% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | — | Hold | — | Downgrade | 17.08.26on TipRanks 12:00 | −66.5%next day +13.0% · 5 days +1.2% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | — | Hold | — | Downgrade | 17.08.26on TipRanks 09:35 | −66.5%next day +13.0% · 5 days +1.2% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $39.00 | Buy | +1,204.3% | Reiterated | 17.08.26on TipRanks 08:30 | −66.5%next day +13.0% · 5 days +1.2% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $40.00 | Buy | +1,237.8% | Initiated | 16.07.26on TipRanks Jul 15 16:20 | −5.3%next day +3.0% · 5 days −2.7% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $68.00 | Buy | +2,174.2% | Reiterated | 24.06.26on TipRanks 16:35 | −4.9%next day +0.4% · 5 days +0.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering EyePoint Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.67 at a price of $3.27 (+532.0%); now: $18.25 at $2.99 (+510.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 11 | 18 | 24 | 18 | 12 |
| Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.91 (from $-1.09 to $-0.60). Last quarter: $-1.09.
Sales
Next quarter’s sales estimate — $0M (from $0M to $1M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About EyePoint Pharmaceuticals
- CEO: Jay S. Duker
- Employees: 214
- 480 Pleasant Street, Watertown, MA, 02472, US
- www.eyepoint.bio
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Data from the stock’s TipRanks forecast page, read 87 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗